Octreotide scan
Type of medical imaging / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Octreoscan?
Summarize this article for a 10 year old
An octreotide scan is a type of SPECT scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis. It is also called somatostatin receptor scintigraphy (SRS). Octreotide, a drug similar to somatostatin, is radiolabeled with indium-111,[1] and is injected into a vein and travels through the bloodstream. The radioactive octreotide attaches to tumor cells that have receptors for somatostatin (i.e. gastrinoma, glucagonoma, etc.). A gamma camera detects the radioactive octreotide, and makes pictures showing where the tumor cells are in the body, typically by a SPECT technique. A technetium-99m based radiopharmaceutical kit is also available.[2][3]
Octreotide scan | |
---|---|
Synonyms | ocreoscan |
ICD-9-CM | 92.18 |
OPS-301 code | 3-70c |
Octreotide scanning is reported to have a sensitivity between 75% and 100% for detecting pancreatic neuroendocrine tumors.[4]
Instead of gamma-emitting 111In, certain octreotide derivatives such as edotreotide (DOTATOC) or DOTATATE are able to be linked by chelation to positron-emitting isotopes such as gallium-68 and copper-64 which in turn can be evaluated with more precise (compared with SPECT) scanning techniques such as PET-CT. Thus, the octreotide scan is now being replaced in most centers with gallium-68 DOTATATE and copper-64 DOTATATE scans. Somatostatin receptor imaging can now be performed with positron emission tomography (PET) which offers higher resolution and more rapid imaging.[5]